Suspension of trading
Cerevel Therapeutics Holdings, Inc. Share Price
Stocks
CERE
US15678U1280
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.96 USD | +0.74% |
|
-.--% | - |
| Market Cap | 8.19B 7.18B 6.67B 6.13B 11.54B 791B 11.72B 79.43B 31.05B 387B 30.75B 30.08B 1,336B | P/E 2022 |
-13.6x | P/E 2023 | -15.9x |
|---|---|---|---|---|---|
| Enterprise Value | 7.5B 6.57B 6.1B 5.61B 10.56B 724B 10.73B 72.68B 28.42B 354B 28.14B 27.53B 1,223B | EV / Sales 2022 |
-
| EV / Sales 2023 | - |
| Free-Float |
93.64% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 day | +0.74% |
| 3 years | 19.59 |  | 44.99 |
| 5 years | 19.59 | | 46.16 |
| 10 years | 9 | | 46.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Renger
CTO | Chief Tech/Sci/R&D Officer | 57 | 30/04/2019 |
Matthew Calistri
IRC | Investor Relations Contact | - | - |
Paul Burgess
PRN | Corporate Officer/Principal | 53 | 19/06/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Deborah Baron
BRD | Director/Board Member | 57 | 19/01/2021 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 01/08/24 | Issuer sale | Chief Medical Officer | 1,495,399 | 0.8208% | ||
| 01/08/24 | Bain Capital Private Equity LP
| Issuer sale | Company | 65,679,781 | 36.0492% | |
| 01/08/24 | Issuer sale | Executive/Senior Manager | 222,723 | 0.1222% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -.--% | -.--% | +52.46% | 8.19B | |
| -0.43% | -1.26% | +52.13% | +85.69% | 55.57B | |
| -0.24% | -0.37% | +57.02% | +54.21% | 54.26B | |
| -0.54% | +1.58% | -15.68% | -15.43% | 23.35B | |
| -1.82% | -3.15% | +3.76% | +405.88% | 23.54B | |
| +0.05% | +1.68% | +38.71% | -4.57% | 20.32B | |
| +3.16% | +2.74% | +37.33% | -31.36% | 17.36B | |
| +1.08% | +3.77% | +36.92% | +593.96% | 15.59B | |
| +0.43% | -1.67% | +166.53% | +299.61% | 14.96B | |
| -2.03% | -1.42% | +24.22% | +179.23% | 14.11B | |
| Average | +0.04% | -0.20% | +40.09% | +161.97% | 24.72B | |
| Weighted average by Cap. | -0.14% | -0.23% | +42.69% | +133.32% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | - | - |
| Net income | -352M -308M -286M -263M -495M -33.94B -503M -3.41B -1.33B -16.59B -1.32B -1.29B -57.33B | -433M -379M -353M -324M -610M -41.79B -619M -4.2B -1.64B -20.43B -1.62B -1.59B -70.59B |
| Net Debt | -523M -459M -426M -391M -737M -50.52B -749M -5.07B -1.98B -24.7B -1.96B -1.92B -85.34B | -695M -610M -566M -520M -980M -67.14B -995M -6.74B -2.64B -32.83B -2.61B -2.55B -113B |
Employees
355
- Stock Market
- Stocks
- CERE Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition